A new randomized clinical trial found that psilocybin therapy reduced symptoms of depression in frontline clinicians affected by the COVID-19 pandemic, with effects lasting up to 6 months.
A recent study examined how prior SARS-CoV-2 vaccination influences innate and adaptive immune responses in breakthrough infections, revealing distinct immune activation patterns.
This respiratory health update covers rising influenza deaths, the spread of new SARS-CoV-2 variants, shifting reinfection patterns, and cardiovascular risks in children
In this respiratory diseases roundup, researchers examine COVID-19 protection, hospitalization rates, long COVID predictors, and rare disease mortality risks.
In this respiratory disease roundup, experts examine the rising cases of human metapneumovirus in China, new research on COVID-19’s long-term effects on kidney function, the effectiveness of...
In this respiratory disease roundup, experts discuss the rising concerns over new cases of avian influenza in young people, the FDA's emergency approval of pemivibart monoclonal antibody for COVID-19, the...
This respiratory health roundup highlights the emerging links between lung and brain health in long COVID, rising avian flu cases in humans and animals, additional insights into the lasting health impacts...
A new study finds similar in-hospital mortality rates for health care-associated COVID-19 and influenza, highlighting the ongoing clinical burden of both diseases in hospitalized patients.
A large cohort study from the Czech Republic suggests that molnupiravir reduced both all-cause and COVID-19-related mortality in adult patients during the Omicron outbreak.
In a study of more than 600,000 pediatric patients, researchers found a higher risk of type 2 diabetes within 6 months of a COVID-19 diagnosis compared with other respiratory infections, especially among...
